Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Debt (2021 - 2025)

Candel Therapeutics' Non-Current Debt history spans 3 years, with the latest figure at $11.6 million for Q4 2023.

  • On a quarterly basis, Non-Current Debt fell 42.42% to $11.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $11.6 million, a 42.42% decrease, with the full-year FY2023 number at $11.6 million, down 42.42% from a year prior.
  • Non-Current Debt hit $11.6 million in Q4 2023 for Candel Therapeutics, down from $14.3 million in the prior quarter.
  • Over the last five years, Non-Current Debt for CADL hit a ceiling of $20.2 million in Q4 2022 and a floor of $560000.0 in Q4 2021.
  • Historically, Non-Current Debt has averaged $11.5 million across 3 years, with a median of $14.3 million in 2023.
  • Biggest five-year swings in Non-Current Debt: surged 3507.5% in 2022 and later tumbled 42.42% in 2023.
  • Tracing CADL's Non-Current Debt over 3 years: stood at $560000.0 in 2021, then surged by 3507.5% to $20.2 million in 2022, then tumbled by 42.42% to $11.6 million in 2023.
  • Business Quant data shows Non-Current Debt for CADL at $11.6 million in Q4 2023, $14.3 million in Q3 2023, and $16.7 million in Q2 2023.